Mazyar Shadman, MD, MPH, explains the current standard-of-care treatment for patients with chronic lymphocytic leukemia and details the factors he considers when choosing an appropriate therapy.
Advancing BTKis in R/R CLL/SLL: Highlights from ASH 2023
Dr Mazyar Shadman reviews emerging targeted therapies shaping the treatment landscape and optimal sequencing in CLL.
An overview of highlights from ASH 2023 on integrating BTK inhibitors into frontline CLL therapy.
Dr Shadman provides an overview of zanubrutinib efficacy and safety data for relapsed/refractory CLL from the Phase 2 ALPINE trial.
Expert perspective on evolving data and strategies for managing relapsed/refractory CLL.
Dr Shadman provides insightful discussion on optimizing outcomes with BTK inhibition in CLL through adverse event mitigation and sustaining treatment in later lines.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
2
FDA Approves Liso-Cel as First CAR T-Cell Therapy for Marginal Zone Lymphoma
3
Lurbinectedin Contributes to Maintenance of Response in ES-SCLC
4
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
5
